A Phase 1/2 trial with ITI-214 in patients with Parkinson's disease

Trial Profile

A Phase 1/2 trial with ITI-214 in patients with Parkinson's disease

Planning
Phase of Trial: Phase I/II

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs ITI 214 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Mar 2017 New trial record
    • 01 Mar 2017 According to an Intra-Cellular Therapies media release, this trial expected to initiate in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top